Breaking News Instant updates and real-time market news.

FOLD

Amicus

$11.59

-0.28 (-2.36%)

, IDXX

Idexx Laboratories

$249.33

3.62 (1.47%)

04:55
09/14/18
09/14
04:55
09/14/18
04:55

BofA/Merrill to hold a conference

Global Healthcare Conference will be held in London, England on September 11-14.

FOLD

Amicus

$11.59

-0.28 (-2.36%)

IDXX

Idexx Laboratories

$249.33

3.62 (1.47%)

AIMT

Aimmune

$29.19

0.03 (0.10%)

RHHBY

Roche

$0.00

(0.00%)

FMS

Fresenius Medical

$52.05

1.24 (2.44%)

SGMO

Sangamo

$14.75

0.35 (2.43%)

  • 14

    Sep

  • 20

    Sep

FOLD Amicus
$11.59

-0.28 (-2.36%)

10/04/17
BOFA
10/04/17
NO CHANGE
Target $20
BOFA
Buy
Amicus price target raised to $20 from $15 at BofA/Merrill
BofA/Merrill analyst Tazeen Ahmad raised Amicus' price target to $20 from $15 saying the Phase 1/2 trial results of ATB200/AT2221 in Pompe disease were impressive. The analyst thinks the strong data justifies progression into pivotal trials and may result in an accelerated approval path. Ahmad rates Amicus a Buy.
05/08/18
JPMS
05/08/18
NO CHANGE
JPMS
Amicus lower on Pompe program commentary, says JPMorgan
JPMorgan analyst Anupam Rama attributes today's post-earnings weakness in shares of Amicus Therapeutics to "conservative commentary" on the call related to the Pompe program. The analyst, however, does not believe that the regulatory scenarios he outlined last month for the program have fundamentally changed. Nonetheless, Rama thinks commentary on the call, particularly on timing, was perceived as cautious. Amicus shares are down 7.5% to $13.49 in midday trading.
04/11/18
JPMS
04/11/18
NO CHANGE
JPMS
Overweight
Amicus risk/reward favorable into regulatory update, says JPMorgan
JPMorgan analyst Anupam Rama notes that a regulatory update for Amicus Therapeutics' Pompe program is expected in Q2. The analyst continues to like the reward/risk profile of the shares going into the update. An accelerated approval path forward is "very much on the table," based on the strength of the Phase 1/2 data, Rama tells investors in a research note. He sees "more win scenarios than lose." The analyst believes Amicus shares can rally 30%-50% should an accelerated approval path forward emerge. Rama keeps an Overweight rating on Amicus with a $19 price target.
08/17/18
CHDN
08/17/18
DOWNGRADE
CHDN
Neutral
Amicus downgraded to Neutral from Buy at Chardan
IDXX Idexx Laboratories
$249.33

3.62 (1.47%)

06/01/18
FBCO
06/01/18
NO CHANGE
Target $228
FBCO
Outperform
Idexx Laboratories price target raised to $228 from $209 at Credit Suisse
Credit Suisse analyst Erin Wilson Wright raised her price target for IDEXX Laboratories to $228 from $209 and maintained an Outperform rating on the shares following a meeting with the company's CEO and CFO, citing a greater conviction in the company's long-term growth prospects. At the meeting, the analyst noted that IDEXX highlighted the company's sustainable leadership position with innovative testing capabilities, "robust" commercial strategy and innovative testing capabilities.
08/01/18
PIPR
08/01/18
NO CHANGE
Target $236
PIPR
Overweight
Idexx Laboratories price target raised to $236 from $211 at Piper Jaffray
Piper Jaffray analyst William Quirk raised his price target on Idexx Laboratories to $236 and kept his Overweight rating after its Q2 earnings beat and raise of FY18 organic revenue growth outlook. The analyst expects continued favorable conditions in the Companion Animal Group to benefit the stock, raising his target forward earnings price multiple to 46-times from 42-times.
05/07/18
ADAM
05/07/18
NO CHANGE
Target $225
ADAM
Buy
Idexx Laboratories price target raised to $225 from $215 at Canaccord
Canaccord analyst Mark Massaro raised his price target on Idexx Laboratories to $225 from $215 following strong Q1 results. The analyst cited its raised organic growth guidance, new products, intact positive trends, and strong global execution. Massaro reiterated his Buy rating on Idexx Laboratories shares.
06/15/18
ADAM
06/15/18
NO CHANGE
Target $123
ADAM
Buy
Heska price target raised to $123 from $115 at Canaccord
After Heska (HSKA) announced after the close a contract win to supply in-clinic diagnostic equipment and supplies to Pathway Vet Alliance, Canaccord analyst Mark Massaro said management confirmed that the multi-year deal was a competitive win, mostly from Idexx (IDXX). He sees the deal positioning Heska for upside in 2019 and 2020 and raised his price target on the stock to $123 from $115. Massaro keeps a Buy rating on Heska shares.
AIMT Aimmune
$29.19

0.03 (0.10%)

08/13/18
FBCO
08/13/18
NO CHANGE
Target $40
FBCO
Outperform
Aimmune price target lowered to $40 form $47 at Credit Suisse
Credit Suisse analyst Vamil Divan lowered his price target for Aimmune to $40 from $47, while reiterating an Outperform rating on the shares. In conjunction with earnings, the analyst has adjusted his expected sales ramp for AR101, while also increasing his assumptions around expenses that will be required to successfully commercialize the product.
06/12/18
JMPS
06/12/18
NO CHANGE
Target $40
JMPS
Outperform
JMP Securities continues to recommend Aimmune after Dallas named CEO
JMP Securities analyst Liisa Bayko continues to recommend Aimmune (AIMT) shares following the company's "not-so-unexpected announcement" of a new CEO. Stephen Dilly announced plans to retire last fall and the incoming CEO, Jayson Dallas, who was most recently EVP and Chief Commercial Officer of Ultragenyx Pharmaceutical (RARE), has a skillset and expertise that should prove useful ahead of a potential launch of AR101, Bayko tells investors. She thinks a 5x multiple on her estimated peak sales of about $1B for AR101 is "justifiable," noting that this is before considering Aimmune's pipeline for egg and walnut allergy. Bayko keeps an Outperform rating and $40 price target on Aimmune shares.
05/29/18
JMPS
05/29/18
NO CHANGE
JMPS
JMP says AnaptysBio weakness ahead of asthma read-out a buying opportunity
After Aimmune Therapeutics (AIMT) presented new results from its Phase 3 trial of AR101 in peanut allergy at a medical congress, JMP Securities analyst Konstantinos Aprilakis noted that shares of competitor AnaptysBio (ANAB) are off about 42% over the last three months. He remains a buyer of AnaptysBio on any weakness going into the top-line proof of concept data from the Phase 2a trial of ANB020 in eosinophilic asthma, which is expected in Q3. The analyst, who reminds investors that he assigns about $61/share for the eosinophilic asthma indication in his valuation of AnaptysBio, maintains an Outperform rating and $180 price target on AnaptysBio shares, which closed Friday at $77.90.
09/13/18
STFL
09/13/18
INITIATION
Target $33
STFL
Hold
Aimmune initiated with a Hold at Stifel
Stifel analyst Derek Archila initiated Aimmune with a Hold rating and a price target of $33. The analyst contends that its "AR101 is approvable", with a meaningful uptake in the newly created peanut allergy immunotherapy category, which he estimates to become a "$3B market opportunity". Archila further notes that AR101 could achieve 20%-40% market share at its peak, adding that he would recommend the stock at a price below $25 per share.
RHHBY Roche
$0.00

(0.00%)

09/10/18
BOFA
09/10/18
DOWNGRADE
BOFA
Neutral
Roche downgraded to Neutral from Buy at BofA/Merrill
09/13/18
CANT
09/13/18
NO CHANGE
Target $36
CANT
Overweight
Cantor boosts Corbus target to Street-high $36 after Roche study 'fell short'
Cantor Fitzgerald analyst Elemer Piros raised his price target for Corbus Pharmaceuticals to a Street-high $36 following abstracts from the American College of Rheumatology meeting, which is taking place in October. Among the abstracts, Phase 3 data from Roche's (RHHBY) Phase 3 systemic sclerosis study with competitive agent tocilizumab fell short on its primary endpoint in modified Rodnan skin score, Piros tells investors in a research note partially titled "Lenabasum's Gain, Following Tocilizumab's Loss." The analyst believes the results establish Corbus' lenabasum, in Phase 3 now for systemic sclerosis, as the" only compelling treatment option for patients in this rare and life-threatening disease." Further, Additionally, Piros believes lenabasum's resolution of inflammatory activity was further validated in an assessment of interferon response in patients with dermatomyositis. The analyst reiterates an Overweight rating on the shares. Corbus Pharmaceuticals in afternoon trading is up 7.5c to $5.28.
08/28/18
08/28/18
UPGRADE
Target $4

Buy
Affimed N.V. upgraded to Buy after Roche collaboration at Jefferies
As previously reported, Jefferies analyst Maury Raycroft upgraded Affimed N.V. (AFMD) to Buy from Hold, stating that its collaboration with Roche Group's (RHHBY) Genentech to develop and commercialize novel NK cell engagers indicate the intrinsic value in Affimed's platform and approach. Affimed will retain its AFM13 and AFM11 wholly-owned clinical programs and can still partner with other companies, noted Raycroft, who raised his price target on Affimed shares to $4.00 from $1.80.
09/10/18
09/10/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Inogen (INGN) downgraded to Buy from Strong Buy at Needham with analyst Mike Matson citing the potential for slower growth as tougher comps start in the second half of 2018, along with a tighter level of competition from Resmed (RMD) and valuation following the 122% year-to-date run-up in the stock price. 2. UnitedHealth (UNH) and Anthem (ANTM) were downgraded to Neutral from Buy at Citi. 3. Constellation Brands (STZ) downgraded to Hold from Buy at SunTrust with analyst William Chappell saying the company's recent $4B investment in Canopy Growth may "keep a cloud" over the stock for the next few quarters, as there is "little certainty" in the deal's revenue or profit potential. 4. Darden (DRI) downgraded to Neutral from Outperform at Baird with analyst David Tarantino citing its recent strength and recommends a more disciplined approach to buying in the short-term as many restaurant names begin to look extended. 5. Roche (RHHBY) downgraded to Neutral from Buy at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
FMS Fresenius Medical
$52.05

1.24 (2.44%)

08/28/18
HSBC
08/28/18
UPGRADE
HSBC
Buy
Fresenius Medical upgraded to Buy from Hold at HSBC
07/09/18
BOFA
07/09/18
INITIATION
BOFA
Buy
Fresenius Medical reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Patrick Wood reinstated coverage of Fresenius Medical with a Buy rating and price target of EUR 102. The analyst views the shares as attractively valued and believes the potential extension of Medicare Secondary Payer currently attached to the Senate opioid bill could be worth around EUR 18 per share.
07/05/18
07/05/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Munich Re (MURGY) downgraded to Neutral from Overweight at JPMorgan. 2. Domino's Pizza Enterprises (DPZUF) downgraded to Sell from Neutral at Citi. 3. NextEra Energy downgraded to Market Perform from Outperform at Raymond James with analyst Pavel Molchanov saying NextEra's 3.6% yield is the lowest among yieldcos and he recommends waiting for a better entry point. 4. Clean Energy (CLNE) downgraded to Underperform from Market Perform at Raymond James with analyst Pavel Molchanov saying he believes shares reflect "excessive euphoria" over the partnership with Total (TOT). 5. Fresenius Medical (FMS) downgraded to Neutral from Outperform at Credit Suisse. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/05/18
FBCO
07/05/18
DOWNGRADE
FBCO
Neutral
Fresenius Medical downgraded to Neutral from Outperform at Credit Suisse
SGMO Sangamo
$14.75

0.35 (2.43%)

09/06/18
JEFF
09/06/18
NO CHANGE
Target $28
JEFF
Buy
Sangamo selloff yesterday an overreaction, says Jefferies
Jefferies analyst Maury Raycroft views the selloff yesterday in shares of Sangamo Therapeutics as an overreaction. Though Street expectations "were misaligned" heading into the initial genome-editing Mucopolysaccharidosis Type II data reported yesterday, initial results demonstrated success and set the stage for additional validating data, Raycroft tells investors in a research note. He believes Sangamo's platform is "robust/valuable" and points out that the company's expects up to five pivotal programs in next few years. The analyst keeps a Buy rating on the shares with a $28 price target.
04/10/18
JEFF
04/10/18
NO CHANGE
JEFF
Jefferies sees value in Abeona, Sangamo, Ultragenyx after AveXis deal
Jefferies analyst Maury Raycroft believes Novartis' (NVS) acquisition of AveXis (AVXS) provides additional validation for the progress and potential of gene therapy. The deal brings attention to Abeona Therapeutics (ABEO) specifically, based on the company's use of AAV9, which is the same vector AveXis has been evaluating with its lead program AVXS-101, Raycroft tells investors in a research note. He thinks yesterday's takeover puts an updated value on gene therapy, implying long-term potential and "sufficient de-risking has occurred." The analyst feels the premium paid for AveXis shows value in Abeona, Sangamo (SGMO) and Ultragenyx (RARE).
08/09/18
JEFF
08/09/18
NO CHANGE
Target $28
JEFF
Buy
Jefferies sees 'excellent entry point' for Sangamo after data
Jefferies analyst Maury Raycroft believes current share levels offer an "excellent entry point" into Sangamo Therapeutics following the company's hemophilia A data. While early, the data is "looking good," Raycroft tells investors in a research note. He believes Sangamo is aiming for best-in-class versus first-to-market. Two clinical catalysts for Sangamo have now been substantially de-risked, Raycroft contends. He recommends buying the stock and keeps a $28 price target for the shares.
06/20/18
BOFA
06/20/18
INITIATION
Target $24
BOFA
Buy
Sangamo initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Qian Wang initiated Sangamo with a Buy and $24 price target saying it has one of the most advanced pipelines in the clinic using zinc finger protein technology. Wang said Sangamo has established partnerships with major players that validates the technology and expects multiple catalysts throughout 2H 2018 and beyond.

TODAY'S FREE FLY STORIES

ELGX

Endologix

$0.52

-0.0223 (-4.09%)

21:09
02/21/19
02/21
21:09
02/21/19
21:09
Conference/Events
Endologix to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 25

    Feb

XEC

Cimarex Energy

$73.33

-3.05 (-3.99%)

, REN

Resolute Energy

$31.52

-0.98 (-3.02%)

21:05
02/21/19
02/21
21:05
02/21/19
21:05
Conference/Events
Resolute Energy to host special shareholder meeting »

Special Shareholder…

XEC

Cimarex Energy

$73.33

-3.05 (-3.99%)

REN

Resolute Energy

$31.52

-0.98 (-3.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 04

    Mar

  • 22

    May

HRNNF

Hydro One

$0.00

(0.00%)

20:34
02/21/19
02/21
20:34
02/21/19
20:34
Downgrade
Hydro One rating change at National Bank »

Hydro One downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ES

Eversource

$70.50

0.23 (0.33%)

20:26
02/21/19
02/21
20:26
02/21/19
20:26
Downgrade
Eversource rating change at Guggenheim »

Eversource downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 04

    Mar

RUTH

Ruth's Hospitality

$25.01

0.35 (1.42%)

, W

Wayfair

$117.14

-0.87 (-0.74%)

20:25
02/21/19
02/21
20:25
02/21/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

RUTH

Ruth's Hospitality

$25.01

0.35 (1.42%)

W

Wayfair

$117.14

-0.87 (-0.74%)

AN

AutoNation

$38.37

-0.76 (-1.94%)

B

Barnes Group

$61.27

-0.01 (-0.02%)

COG

Cabot Oil & Gas

$24.54

-0.41 (-1.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 27

    Feb

  • 03

    Mar

  • 04

    Mar

DLR

Digital Realty

$116.42

-2.07 (-1.75%)

20:10
02/21/19
02/21
20:10
02/21/19
20:10
Hot Stocks
Digital Realty raises quarterly dividend to $1.08 per share from $1.01 »

The dividend will be paid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

  • 26

    Mar

  • 27

    Mar

  • 18

    Jun

ARDM

Aradigm

$0.00

(0.00%)

20:08
02/21/19
02/21
20:08
02/21/19
20:08
Hot Stocks
Aradigm receives FDA minutes for Type B meeting »

At the Type B meeting,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUN

Sunoco

$29.49

-0.37 (-1.24%)

20:03
02/21/19
02/21
20:03
02/21/19
20:03
Recommendations
Sunoco analyst commentary at MUFG »

Sunoco price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

IMDZ

Immune Design

$5.83

4.405 (309.12%)

19:41
02/21/19
02/21
19:41
02/21/19
19:41
Downgrade
Immune Design rating change at RBC Capital »

Immune Design downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIPS

Vipshop

$6.30

-1 (-13.70%)

19:40
02/21/19
02/21
19:40
02/21/19
19:40
Downgrade
Vipshop rating change at Macquarie »

Vipshop downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

ADBE

Adobe

$257.67

-0.46 (-0.18%)

19:39
02/21/19
02/21
19:39
02/21/19
19:39
Downgrade
Adobe rating change at DZ Bank »

Adobe downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

KL

Kirkland Lake Gold

$36.03

2.6 (7.78%)

19:37
02/21/19
02/21
19:37
02/21/19
19:37
Earnings
Kirkland Lake Gold reports Q4 EPS 52c vs. 31c last year »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

MTN

Vail Resorts

$207.48

-3.69 (-1.75%)

19:34
02/21/19
02/21
19:34
02/21/19
19:34
Hot Stocks
Vail Resorts to buy Falls Creek and Hotham ski resorts in Australia for AUD174M »

Vail Resorts announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$277.43

-0.99 (-0.36%)

19:23
02/21/19
02/21
19:23
02/21/19
19:23
Periodicals
U.S, China resume trade negotiations to hash out structural issues, Reuters says »

Top U.S. and Chinese…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$277.43

-0.99 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Shares

$125.06

-1.41 (-1.11%)

19:10
02/21/19
02/21
19:10
02/21/19
19:10
Hot Stocks
SPDR Gold Shares holdings fall to 789.51MT from 794.50MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOG

Extraction Oil & Gas

$3.81

-0.1 (-2.56%)

, BOOM

DMC Global

$35.37

0.04 (0.11%)

19:05
02/21/19
02/21
19:05
02/21/19
19:05
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

XOG

Extraction Oil & Gas

$3.81

-0.1 (-2.56%)

BOOM

DMC Global

$35.37

0.04 (0.11%)

TTD

Trade Desk

$150.18

0.07 (0.05%)

CATM

Cardtronics

$26.06

-0.98 (-3.62%)

Z

Zillow

$35.03

0.22 (0.63%)

OLED

Universal Display

$118.31

-0.57 (-0.48%)

BYD

Boyd Gaming

$28.28

-0.11 (-0.39%)

FIX

Comfort Systems USA

$51.96

0.32 (0.62%)

CYTK

Cytokinetics

$7.20

-0.14 (-1.91%)

ROKU

Roku

$51.47

-2.16 (-4.03%)

TXMD

TherapeuticsMD

$5.10

-0.36 (-6.59%)

BIDU

Baidu

$171.72

0.64 (0.37%)

CWST

Casella Waste

$33.55

-1.47 (-4.20%)

KEYS

Keysight Technologies

$81.74

0.67 (0.83%)

DAIO

Data I/O

$5.94

-0.04 (-0.67%)

HPE

HP Enterprise

$16.22

0.16 (1.00%)

STMP

Stamps.com

$198.08

-4.03 (-1.99%)

KHC

Kraft Heinz

$48.19

-0.05 (-0.10%)

ASPN

Aspen Aerogels

$3.60

0.03 (0.84%)

DBX

Dropbox

$25.58

0.1 (0.39%)

MDRX

Allscripts

$11.93

-0.21 (-1.73%)

AAOI

Applied Optoelectronics

$14.62

(0.00%)

CASA

Casa Systems

$11.96

-0.02 (-0.17%)

UCTT

Ultra Clean

$12.59

-0.26 (-2.02%)

BJRI

BJ's Restaurants

$51.97

0.75 (1.46%)

BMRN

BioMarin

$88.80

-1.82 (-2.01%)

TGH

Textainer

$13.05

-0.06 (-0.46%)

APPN

Appian

$38.73

0.41 (1.07%)

INFN

Infinera

$4.87

-0.02 (-0.41%)

NVRO

Nevro

$47.27

-1.12 (-2.31%)

FSLR

First Solar

$51.91

0.23 (0.45%)

CENX

Century Aluminum

$9.30

0.12 (1.31%)

UEIC

Universal Electronics

$29.34

0.36 (1.24%)

RMAX

RE/MAX Holdings

$40.34

-0.2 (-0.49%)

STAA

STAAR Surgical

$36.86

0.17 (0.46%)

SLRC

Solar Capital

$21.27

0.34 (1.62%)

IQ

iQIYI

$22.76

0.17 (0.75%)

EHTH

eHealth

$65.58

-0.28 (-0.43%)

PE

Parsley Energy

$17.93

-0.595 (-3.21%)

EXAS

Exact Sciences

$83.30

-0.3 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 03

    Mar

  • 04

    Mar

  • 05

    Mar

  • 06

    Mar

  • 06

    Mar

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

  • 08

    Mar

  • 11

    Mar

  • 13

    Mar

  • 13

    Mar

  • 13

    Mar

  • 20

    Mar

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    Mar

  • 18

    May

  • 22

    May

GM

General Motors

$39.63

-0.33 (-0.83%)

18:54
02/21/19
02/21
18:54
02/21/19
18:54
Periodicals
GM CEO will not appear in front of Canada lawmakers over closure, Reuters says »

General Motors CEO Mary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

CXO

Concho Resources

$103.69

-8.68 (-7.72%)

18:37
02/21/19
02/21
18:37
02/21/19
18:37
Recommendations
Concho Resources analyst commentary at MUFG »

Concho Resources price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 28

    May

KHC

Kraft Heinz

$48.19

-0.05 (-0.10%)

18:37
02/21/19
02/21
18:37
02/21/19
18:37
Hot Stocks
Kraft Heinz confirms quarterly dividend cut to 40c from 62.5c per share »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

KHC

Kraft Heinz

$48.19

-0.05 (-0.10%)

18:32
02/21/19
02/21
18:32
02/21/19
18:32
Hot Stocks
Kraft Heinz says has taken 'remedial measures' on procurement issues »

Says write down reflected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

CZR

Caesars

$9.42

-0.21 (-2.18%)

18:25
02/21/19
02/21
18:25
02/21/19
18:25
Hot Stocks
Breaking Hot Stocks news story on Caesars »

Caesars: Las Vegas FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

RARE

Ultragenyx

$58.16

-2.33 (-3.85%)

18:20
02/21/19
02/21
18:20
02/21/19
18:20
Initiation
Ultragenyx initiated at Raymond James »

Ultragenyx resumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$0.00

(0.00%)

, CPB

Campbell Soup

$35.44

0.26 (0.74%)

18:13
02/21/19
02/21
18:13
02/21/19
18:13
Periodicals
Third Point says confident in Nestle CEO's leadership, Reuters reports »

Third Point told…

NSRGY

Nestle

$0.00

(0.00%)

CPB

Campbell Soup

$35.44

0.26 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    May

STMP

Stamps.com

$198.08

-4.03 (-1.99%)

18:11
02/21/19
02/21
18:11
02/21/19
18:11
Hot Stocks
Breaking Hot Stocks news story on Stamps.com »

Stamps.com drops 50%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

STMP

Stamps.com

$198.08

-4.03 (-1.99%)

18:09
02/21/19
02/21
18:09
02/21/19
18:09
Hot Stocks
Stamps.com to discontinue partnership with USPS »

On its Q4 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.